Tag Archives: vitamin K anatgonist

Background The novel oral anticoagulant (NOAC) agents (dabigatran, rivaroxaban, apixaban) have had a disproportionally poor uptake since their respective launches and National Institute for Health and Care Excellence (NICE) Technology Appraisal in the UK between 2012 and 2013 for their use in stroke prevention in patients with non-valvular atrial fibrillation (NVAF), when compared with our European counterparts; particularly Germany, Holland and France. In the original NICE economic analyses for the NOACs there was a calculated uptake of approximately 20% in the first year,1 the figure currently runs at <8% with many area’s significantly